Literature DB >> 26504183

Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.

Anna B Halpern1, Gary H Lyman2, Thomas J Walsh3, Dimitrios P Kontoyiannis4, Roland B Walter5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26504183      PMCID： PMC4692139          DOI： 10.1182/blood-2015-07-627323

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  104 in total

1.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

2.  Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.

Authors:  S N Wolff; J Fay; D Stevens; R H Herzig; B Pohlman; B Bolwell; J Lynch; S Ericson; C O Freytes; F LeMaistre; R Collins; L Pineiro; J Greer; R Stein; S A Goodman; S Dummer
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

3.  Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.

Authors:  Urshila Durani; Pritish K Tosh; Jason N Barreto; Lynn L Estes; Paul J Jannetto; Aaron J Tande
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

4.  Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.

Authors:  Gloria N Mattiuzzi; Jorge Cortes; Gladys Alvarado; Srdan Verstovsek; Charles Koller; Sherry Pierce; Deborah Blamble; Stefan Faderl; Lianchun Xiao; Mike Hernandez; Hagop Kantarjian
Journal:  Support Care Cancer       Date:  2009-12-03       Impact factor: 3.603

5.  Prospective trial finds nystatin mouthwash effective prophylaxis for pulmonary invasive fungal infections that originate in the throat of patients with hematologic malignancies.

Authors:  R Hu; X Jiang; Y Wu
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

6.  Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia.

Authors:  R S Schwartz; F R Mackintosh; S L Schrier; P L Greenberg
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

7.  Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.

Authors:  Bart J Rijnders; Jan J Cornelissen; Lennert Slobbe; Martin J Becker; Jeanette K Doorduijn; Wim C J Hop; Elisabeth J Ruijgrok; Bob Löwenberg; Arnold Vulto; Pieternella J Lugtenburg; Siem de Marie
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

8.  Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.

Authors:  Yasushi Hiramatsu; Yoshinobu Maeda; Nobuharu Fujii; Takashi Saito; Yuichiro Nawa; Masamichi Hara; Tomofumi Yano; Shoji Asakura; Kazutaka Sunami; Takayuki Tabayashi; Akira Miyata; Ken-Ichi Matsuoka; Katsuji Shinagawa; Kazuma Ikeda; Keitaro Matsuo; Mitsune Tanimoto
Journal:  Int J Hematol       Date:  2008-11-29       Impact factor: 2.490

9.  Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada.

Authors:  Amir A Tahami Monfared; Amy K O'Sullivan; Coleman Rotstein; George Papadopoulos
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

10.  A risk prediction score for invasive mold disease in patients with hematological malignancies.

Authors:  Marta Stanzani; Russell E Lewis; Mauro Fiacchini; Paolo Ricci; Fabio Tumietto; Pierluigi Viale; Simone Ambretti; Michele Baccarani; Michele Cavo; Nicola Vianelli
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240
View more
  14 in total

1.  Fatal Disseminated Infection by Trichosporon asahii Under Voriconazole Therapy in a Patient with Acute Myeloid Leukemia: A Review of Breakthrough Infections by Trichosporon spp.

Authors:  I Ramírez; D Moncada
Journal:  Mycopathologia       Date:  2019-12-18       Impact factor: 2.574

Review 2.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

3.  Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections.

Authors:  Andrew Hsu; Robert Matera; Kendra Vieira; John L Reagan; Dimitrios Farmakiotis
Journal:  Support Care Cancer       Date:  2020-05-21       Impact factor: 3.603

Review 4.  Prophylactic Measures During Induction for Acute Myeloid Leukemia.

Authors:  Matthew W McCarthy; Thomas J Walsh
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

5.  Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions.

Authors:  Michail S Lionakis; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

6.  Voriconazole-Induced Periostitis Mimicking Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation.

Authors:  Karen Sweiss; Annie Oh; Damiano Rondelli; Pritesh Patel
Journal:  Case Rep Infect Dis       Date:  2016-06-14

7.  Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia: A Case Report.

Authors:  Mayur D Mody; Deepak Ravindranathan; Harpaul S Gill; Vamsi K Kota
Journal:  J Investig Med High Impact Case Rep       Date:  2017-02-01

Review 8.  Management of the Older Patient with Myelodysplastic Syndrome.

Authors:  Rory M Shallis; Amer M Zeidan
Journal:  Drugs Aging       Date:  2021-08-03       Impact factor: 3.923

Review 9.  Acute myeloid leukemia: current progress and future directions.

Authors:  Hagop Kantarjian; Tapan Kadia; Courtney DiNardo; Naval Daver; Gautam Borthakur; Elias Jabbour; Guillermo Garcia-Manero; Marina Konopleva; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2021-02-22       Impact factor: 11.037

10.  Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.

Authors:  Mohamed L Sorror; Barry E Storer; Amir T Fathi; Andrew Brunner; Aaron T Gerds; Mikkael A Sekeres; Sudipto Mukherjee; Bruno C Medeiros; Eunice S Wang; Pankit Vachhani; Paul J Shami; Esteban Peña; Mahmoud Elsawy; Kehinde Adekola; Selina Luger; Maria R Baer; David Rizzieri; Tanya M Wildes; Jamie Koprivnikar; Julie Smith; Mitchell Garrison; Kiarash Kojouri; Wendy Leisenring; Lynn Onstad; Jennifer E Nyland; Pamela S Becker; Jeannine S McCune; Stephanie J Lee; Brenda M Sandmaier; Frederick R Appelbaum; Elihu H Estey
Journal:  Blood       Date:  2021-08-05       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.